Match!
Subodh Verma
St. Michael's Hospital
669Publications
70H-index
20.1kCitations
Publications 692
Newest
#1C. MazerH-Index: 1
#2Amel ArnaoutH-Index: 3
Last.Ronald GoldenbergH-Index: 14
view all 7 authors...
Purpose of reviewThe aim of this article is to provide practical recommendations on safe initiation of sodium-glucose cotransporter 2 (SGLT2) inhibitors to in-patients as well as management of those who are already on SGLT2 inhibitors.Recent findingsRobust data from stable outpatient cohorts indicat
Source
#1Subodh Verma (St. Michael's Hospital)H-Index: 70
#2Qiuhe Ji (Fourth Military Medical University)H-Index: 20
Last.Jyothis T. George (Boehringer Ingelheim)H-Index: 21
view all 12 authors...
Source
#1Eileen O'Meara (UdeM: Université de Montréal)H-Index: 28
#2Michael McDonald (UHN: University Health Network)H-Index: 13
Last.Sheri L. Koshman (U of A: University of Alberta)H-Index: 8
view all 45 authors...
Abstract In this update, we focus on selected topics of high clinical relevance for health care providers who treat patients with heart failure (HF), on the basis of clinical trials published after 2017. Our objective was to review the evidence, and provide recommendations and practical tips regarding the management of candidates for the following HF therapies: (1) transcatheter mitral valve repair in HF with reduced ejection fraction; (2) a novel treatment for transthyretin amyloidosis or trans...
Source
#1Abhinav Sharma (MUHC: McGill University Health Centre)H-Index: 1
#2Subodh Verma (St. Michael's Hospital)H-Index: 70
Abstract The growing global burden of type 2 diabetes mellitus confers significant morbidity and mortality in addition to significant cost to local health-care systems. In recent years, 2 classes of therapies have shown some promise in reducing the risk of adverse cardiovascular (CV) events: 1) glucagon-like-peptide-1 (GLP-1) receptor agonists and 2) sodium-glucose cotransporter-2 (SGLT-2) inhibitors. The mechanisms whereby these therapies reduce the risk of adverse CV outcomes are emerging. Bot...
1 CitationsSource
#1Mikhail Kosiborod (UMKC: University of Missouri–Kansas City)H-Index: 46
#2Pardeep S. Jhund (BHF: British Heart Foundation)H-Index: 36
Last.John J.V. McMurray (BHF: British Heart Foundation)H-Index: 151
view all 22 authors...
Background: Goals of management in patients with heart failure and reduced ejection fraction (HFrEF) include reducing death and hospitalizations, and improving health status (symptoms, physical fun...
4 CitationsSource
#1Javed Butler (UMMC: University of Mississippi Medical Center)H-Index: 37
#2Yehuda HandelsmanH-Index: 41
Last.Subodh Verma (St. Michael's Hospital)H-Index: 70
view all 4 authors...
Source
Abstract Pulmonary arterial hypertension (PAH) is a rare, but progressive and devastating vascular disease with few treatment options to prevent the advancement to right ventricular dysfunction hypertrophy and failure. Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, enhances urinary glucose excretion as well as reduces cardiovascular events and mortality in individuals with type 2 diabetes. While empagliflozin has been reported to lower systemic hypertension due to increased d...
Source
#1Subodh Verma (St. Michael's Hospital)H-Index: 70
#2Deepak L. Bhatt (Brigham and Women's Hospital)H-Index: 122
Source
#1R. Ribeiro (St. Michael's Hospital)H-Index: 2
#2Bobby Yanagawa (St. Michael's Hospital)H-Index: 20
Last.Jan O. Friedrich (U of T: University of Toronto)H-Index: 38
view all 7 authors...
Source
#1Subodh Verma (St. Michael's Hospital)H-Index: 70
Source
12345678910